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ABSTRACT
Objectives: Using a prospective study design, we
aimed to characterise the effect of acute kidney injury
(AKI) on long-term changes in renal function in a
general hospital population.
Participants: Hospitalised patients with AKI (exposed)
and hospitalised patients without AKI (non-exposed),
recruited at 3 months after hospital admission.
Design: Prospective, matched parallel group cohort
study, in which renal function and proteinuria were
measured at 3 months, 1 year and 3 years.
Setting: Single UK centre.
Clinical end points: Clinical end points at 3 years
were comparison of the following variables between
exposed and non-exposed groups: renal function,
prevalence of proteinuria and albuminuria and chronic
kidney disease (CKD) progression/development at each
time point. CKD progression was defined as a decrease
in the estimated glomerular filtration rate (eGFR) of
≥25% associated with a decline in eGFR stage.
Results: 300 exposed and non-exposed patients were
successfully matched 1:1 for age and baseline renal
function; 70% of the exposed group had AKI stage
1. During follow-up, the AKI group had lower eGFR
than non-exposed patients at each time point. At
3 years, the mean eGFR was 60.7±21 mL/min/1.73 m2
in the AKI group compared with 68.4±21 mL/min/
1.73 m2 in the non-exposed group, p=0.003. CKD
development or progression at 3 years occurred in 30
(24.6%) of the AKI group compared with 10 (7.5%) of
the non-exposed group, p<0.001. Albuminuria was
more common in the AKI group, and increased with
AKI severity. Factors independently associated with
CKD development/progression after AKI were non-
recovery at 90 days, male gender, diabetes and
recurrent AKI.
Conclusions: AKI is associated with deterioration in
renal function to 3 years, even in an unselected
population with predominantly AKI stage 1. Non-
recovery from AKI is an important factor determining
long-term outcome.
INTRODUCTION
Acute kidney injury (AKI) is common, affect-
ing up to 20% of hospitalised patients.1 In
addition to well-established short-term risks,
there is growing recognition that AKI is
associated with adverse long-term conse-
quences.2 Large retrospective analyses of
administrative data sets have demonstrated
associations between AKI and subsequent
increased risk of mortality, chronic kidney
disease (CKD) progression and cardiovascu-
lar complications.
Despite these ﬁndings, there remains a
need for large-scale prospective observational
studies. Prospective studies provide more
robust evidence with standardised follow-up
assessments that reduce the risk of ascertain-
ment bias, as well as more detailed patient
endotyping that lessens the risk of confound-
ing. In addition, it is crucial that studies are
generalisable to the wider AKI population,
rather than focussing on AKI in speciﬁc cir-
cumstances. AKI has many different causes
and can affect individuals in a wide variety of
healthcare settings, and it is plausible that
this varied population could have diverse out-
comes. Furthermore, detailed and accurate
characterisation of individuals with AKI is
required to determine factors associated with
Strengths and limitations of this study
▪ In contrast to much of the previous work exam-
ining long-term outcomes after acute kidney
injury (AKI), prospective design with matched
cohorts and standardised sampling times
reduces chances of residual confounding when
compared with retrospective studies.
▪ General hospitalised patients with AKI have not
been well studied previously, despite making up
the majority of those affected by AKI.
▪ This is a pilot study, designed to test method-
ology and determine initial results prior to a
larger scale study; therefore, sample size is
limited to 300.
▪ Prospective study design prevents determination
of whether patients had pre-existing proteinuria.
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good and poor outcomes. This includes better descrip-
tion of the natural history of renal impairment following
AKI and the point at which CKD development or pro-
gression occurs.
This evidence gap is being addressed through
large-scale prospective observational studies currently in
progress. The AKI Risk in Derby (ARID) study and The
ASsessment, Serial Evaluation, and Subsequent Sequelae
in Acute Kidney Injury (ASSESS-AKI) study3 aim to
investigate long-term effects of AKI in unselected gener-
alisable hospitalised populations. We have previously
reported evidence of renal impairment and proteinuria
persisting to 1 year after AKI from the ARID pilot study;4
we now present the 3-year follow-up results.
METHODS
Study design and methodology is reported in full else-
where.4 In brief, a prospective parallel group pilot
cohort study with intergroup matching was performed
between September 2011 and October 2012 at the Royal
Derby Hospital to conﬁrm feasibility of the recruitment
and data collection methodology for the main ARID
main study (ISRCTN25405995). The Royal Derby
Hospital is a 1139-bed teaching hospital that provides all
major medical and surgical specialties excepting cardio-
thoracic surgery and has a tertiary referral nephrology
unit. A single chemical pathology laboratory covers all
inpatient areas and referring primary care centres.
Approvals for the study were obtained from Derbyshire
Research Ethics Committee and the National
Information Governance Board. All patients provided
written, informed consent.
Participants were patients who sustained AKI at any
point during a hospital admission (exposed group) or
emergency admissions who did not sustain AKI (non-
exposed group). Potential participants were identiﬁed
through automated screening of results from an elec-
tronic AKI detection system as previously described.4 5
AKI was deﬁned by modiﬁed Acute Kidney Injury
Network (AKIN) criteria (the most current at the time
of study inception). Baseline creatinine was the most
recent stable serum creatinine from up to 12 months
previously; patients were excluded if no baseline value
was available. All AKI episodes were subsequently adjudi-
cated by a member of the research team to conﬁrm that
AKI rather than CKD progression had been detected.
Exposed and non-exposed patients were matched 1:1 for
baseline estimated glomerular ﬁltration rate (eGFR)
stage (eGFR>60 mL/min/1.73 m2, eGFR stage 3A, 3B or
4) and age ±5 years. Exclusion criteria were age <18 or
>85 years, death during admission, receiving palliative
care and language barrier preventing remote consent
(<1% of local population being non-English speaking).
Serum creatinine, eGFR (calculated using CKD
Epidemiology Collaboration Equation) and urinary
protein excretion were measured at 3 months, 1 year
and 3 years after index blood test; for the exposed
group, this was day of AKI onset and for the non-
exposed group, this was ﬁrst blood test in admission.
Participants were asked not to eat cooked meat for at
least 12 hours before giving a blood sample and were
asked to provide an early morning urine specimen.
Samples were handled separately from routine clinical
samples with rapid transfer and analysis within 7 hours
in the central hospital laboratory. Hospital admission
data, Charlson score, coded comorbidities and mortality
were extracted from the hospital patient administration
system. Aetiology of AKI was determined by manual
review of electronic patient records. Cross referencing
with the local renal database was used to track initiation
of long-term renal-replacement therapy (RRT).
Clinical end points at 3 years were comparison of the
following variables between the exposed and non-
exposed groups: renal function, prevalence of protein-
uria and albuminuria and CKD progression/develop-
ment at each time point. CKD progression was deﬁned
as a decrease in eGFR of ≥25% associated with a decline
in eGFR stage. This deﬁnition was used in individuals
with known CKD at baseline and those with baseline
eGFR>60 mL/min/1.73 m2. Proteinuria was deﬁned as
PCR>15 mg/mmol and albuminuria as ACR>3.0 mg/
mmol. Mortality and a composite renal end point of
doubling of serum creatinine, initiation of RRT or eGFR
<15 mL/min/1.73 m2 were also recorded.
Statistical analysis
Parametric data are expressed as mean±SD and non-
parametric as median (IQR). The χ2 test was used to
compare categorical data. The t-test or Mann-Whitney
test was used to compare parametric or non-parametric
data, respectively. Binary logistic regression analysis was
used to test signiﬁcant univariate associations with CKD
progression. p≤0.05 was considered statistically signiﬁ-
cant. Statistical analysis was performed with SPSS V.22.
RESULTS
Participant disposition
A total of 2036 patients (975 AKI and 1061 non-exposed
patients) met inclusion criteria and were invited to par-
ticipate. Three hundred and sixty-seven consented to
take part and 300 were successfully matched 1:1 accord-
ing to age and baseline renal function. Figure 1 is a
study ﬂow diagram, showing the numbers of participants
at each stage of the study.
Eight people were lost to follow-up after matching.
One person withdrew their initial consent, two were no
longer interested, one could not participate because of
ill health and one for family reasons, one failed to
submit samples and we were unable to contact two
people.
Patient demographics
Demographic information is summarised in table 1.
There were no signiﬁcant differences between the
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exposed and non-exposed groups in age, baseline eGFR
stage, eGFR and serum creatinine. Coded comorbidities
were similar, though a higher proportion of the exposed
group had cancer than non-exposed (eight in the
exposed group compared with none in the non-exposed
group, p=0.003).
One hundred and ﬁve (70%) in the exposed group
had AKI stage 1, 24 (16%) had stage 2 and 21 (14%)
had stage 3 AKI. Only one person required dialysis
during their acute admission. The majority of AKI was
community-acquired, deﬁned as AKI detected on the
ﬁrst day of hospital admission; this was seen in 103
patients (74%). The most common cause of AKI was
multifactorial in 72 (48%) cases; 33 (46%) of these
patients were in the perioperative period. Twenty
patients (13%) had AKI due to sepsis alone, 12 (8%)
due to hypovolaemia and 11 (7%) had urinary tract
obstruction. The remaining 24% had a variety of aetiolo-
gies including AKI in the setting of acute cardiac
disease, contrast-induced AKI and intrinsic renal dis-
eases (in 11 patients (7%)).
Renal function
eGFR was signiﬁcantly lower in the exposed group
when compared with the non-exposed group at each
point of follow-up, and this difference persisted to
Figure 1 Study flow diagram.
Table 1 Baseline characteristics of acute kidney injury and non-exposed groups
Non-exposed (n=150) AKI (n=150) p Value
Median age (years) 71 (IQR 63–79) 72 (IQR 63–77) 0.6
Number of male patients 85 (57%) 88 (59%) 0.7
Median baseline Charlson score 0 (IQR 0–1) 1 (IQR 0–2) 0.2
Mean baseline creatinine (µmol/L) 93±32 98±33 0.2
Mean baseline eGFR (mL/min/1.73 m2) 71±21 68±19 0.1
Proportion of patients per eGFR stage
eGFR>60 103 (68.7%) 99 (66.0%) 0.7
3A 31 (20.7%) 38 (25.3%)
3B 12 (8.0%) 11 (7.3%)
4 4 (2.7%) 2 (1.3%)
Diabetes mellitus 22 (15%) 28 (20%) 0.3
Renal disease 12 (8%) 19 (13%) 0.1
Cancer 0 (0%) 8 (5.6%) 0.003
Previous MI 15 (10.0%) 15 (10.0%) 0.93
Previous stroke 2 (1.3%) 0 0.49
Heart failure 6 (4.0%) 6 (4.0%) 1.0
Peripheral vascular disease 3 (2.0%) 4 (2.7%) 0.67
Pulmonary disease 14 (9.3%) 13 (8.7%) 0.9
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3 years (ﬁgure 2). At 3 years after AKI, the mean eGFR
was 60.7±21 mL/min in the exposed group compared
with 68.4±21 mL/min in the non-exposed group,
p=0.003. A higher proportion of those in the AKI
group had CKD progression between baseline and
each follow-up point. At 3 years, the number of AKI
patients with CKD progression was 30 (24.6%), com-
pared with 10 (7.5%) of the non-exposed group,
p<0.001. Of these, CKD development or progression
was already evident at 3 months in 14 (46.7%) exposed
patients compared with none of the non-exposed,
p=0.007. There was no difference between the propor-
tions of the exposed and non-exposed groups that had
CKD progression between 3 months and 3-year
follow-up. Similar associations were seen when only the
105 matched pairs with stage 1 AKI were studied; CKD
progression from baseline to 3 years was seen in 21
(24.1%) AKI patients compared with 7 (7.4%) non-
exposed patients, p=0.002.
There were 29 deaths in the 3-year follow-up period;
17 (11.3%) in the AKI group and 12 (8.0%) in the non-
exposed group, p=0.3. Reaching the composite renal
end point was uncommon, occurring in three AKI and
four non-exposed patients, p=0.7. A greater proportion
of the exposed group had at least one further episode of
AKI during the follow-up period; this was seen in 45
(30%) exposed group compared with 28 (18.7%) non-
exposed, p=0.02. Twenty-three (15.3%) of the exposed
group were under follow-up at 3 months; this fell to six
(7.4%) of the exposed group at 3 years.
Proteinuria
Albuminuria (ACR≥3 mg/mmol) and proteinuria
(PCR≥15 mg/mmol) were relatively common, but to a
greater extent in the exposed group at each time point
(table 2). At 3 years, 46 (40.7%) of the exposed group had
albuminuria compared with 26 (21.1%) non-exposed,
p=0.001. Proteinuria was predominantly low grade; at
3 years, the median ACR was 1.7 mg/mmol in exposed and
0.75 mg/mmol in non-exposed groups (p=0.003) and the
median PCR was 13 mg/mmol in the exposed group and
10 mg/mmol in the non-exposed group (p=0.006). The
ACR/PCR ratio was low in the exposed and non-exposed
groups, with median values of <0.4 at all time points.
There was a graded relationship between AKI severity
and proportion of participants with albuminuria
(table 3). The proportion of individuals with albumin-
uria was lowest in non-exposed, and increased as the
severity of AKI increased. The same pattern was seen
when participants without diabetes were analysed.
Risk factors for CKD progression in those with AKI
Associations with CKD progression after AKI were inves-
tigated through a subset analysis of only the 194 indivi-
duals who sustained AKI, matched and unmatched
participants. Comparisons were made between those
who did and did not have CKD progression at 3 years.
The median age of this subgroup was 71 years (IQR 15)
and mean baseline eGFR 63.7±19.6 mL/min, with 84
(43.3%) having pre-existing known CKD (predomin-
antly CKD G3a). The majority (59.3%) were men and
41 (22.5%) had diabetes at baseline. Again, AKI stage 1
was the most common; 138 (71.1%) had stage 1, 31
(16.0%) had stage 2 and 25 (12.9%) had stage 3.
At 3 years, CKD progression had occurred in 39 parti-
cipants (25.3%). The pattern of eGFR over time in
those who did and did not have CKD progression at
3 years is shown in ﬁgure 3. The majority of those who
did not show CKD development or progression at
3 years had recovery of renal function at 3 months after
AKI. Complete recovery at 3 months (deﬁned as creatin-
ine <1.1×baseline creatinine) was seen in 85 (74%) of
those who did not have CKD progression at 3 years
when compared with 10 (25.6%) who did, p<0.001.
Univariate and multivariate associations with CKD pro-
gression at 3 years are shown in table 4. On binary logis-
tic regression, male gender, greater decline in eGFR at
3 months and diabetes remained independently asso-
ciated with CKD progression. When decline in eGFR at
3 months was removed from the model, age and dia-
betes remained independent predictors. Analysis of asso-
ciations with composite renal end point was limited by
small numbers. This occurred in only six individuals
(3.1%); four of these individuals had CKD 4 at baseline
and ﬁve sustained AKI stage 3.
Sixty-four (33%) had at least one further AKI during
the 3-year follow-up period. Recurrent AKI was asso-
ciated with CKD progression during the follow-up
period; 10 (22.7%) of those with recurrent AKI had CKD
Figure 2 Mean estimated glomerular filtration rate (eGFR) at
each assessment point in non-exposed (no acute kidney
injury (AKI)) compared with matched participants with AKI.
Estimated GFR measurements are included for inhospital time
points to illustrate the effect of AKI; however, the absolute
eGFR values at these time points should be interpreted with
caution as patients are not in steady state. *p<0.001,
**p=0.001, ***p=0.003. Error bars: 95% CI.
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progression between 3 months and 3 years after the initial
AKI episode, compared with 10 (9%) of those without
recurrent AKI (p=0.02). This association remained an
independent predictor when corrected for age, baseline
eGFR and gender (OR 3.48, CI 1.28 to 9.46).
DISCUSSION
Our results demonstrate that long-term reductions in
renal function and proteinuria are associated with AKI.
This builds on our previous work, and we now show that
this association persists to 3 years following AKI, even in
a general hospital population with predominantly AKI
stage 1.
Epidemiological evidence consistently demonstrates
an association between AKI and adverse long-term con-
sequences, including CKD development and progres-
sion.2 The nature of the association is thought to be
bidirectional; CKD is a risk factor for AKI, but also it is
biologically plausible that AKI can cause CKD. Animal
models demonstrate that the processes of CKD progres-
sion can persist and self-perpetuate after an acute
insult.6 In addition, studies blocking ﬁbrogenic signal-
ling cascades following animal models of AKI demon-
strate a reduction in subsequent development of
tubulointerstitial ﬁbrosis.7 In clinical studies, causality is
supported by the association of AKI and subsequent
CKD development in children, who do not have the
same baseline burden of comorbidity which can con-
found adult studies.8 9 In addition, examination of the
trajectory of eGFR decline in CKD patients suggests that
this is not linear, and may therefore be punctuated by
acute episodes of deterioration which change the
pattern of decline.10
Our results are consistent with this evidence, conﬁrm-
ing the association between AKI and subsequent CKD
progression in an unselected group of AKI survivors in a
general hospital setting. Importantly, this association was
seen in those individuals who sustained stage 1 AKI,
demonstrating the relevance to even those with less
severe renal injury. Although we observed a low com-
bined risk of progression to end-stage kidney failure
(ESKD) in this group over a 3-year follow-up period, the
incidence of CKD progression was much higher. It is
possible that over a longer follow-up period, a greater
proportion of these patients would progress to ESKD,
although further study is required to substantiate that.
Table 2 Number (%) of acute kidney injury and non-exposed groups with albuminuria (ACR ≥3 mg/mmol) and proteinuria
(PCR ≥15 mg/mmol) at each time point
3 months 1 year 3 years
AKI
(n=150)
Non-exposed
(n=150)
AKI
(n=137)
Non-exposed
(n=147)
AKI
(n=125)
Non-exposed
(n=138)
Albuminuria
number (%)
48 (36.6)* 30 (20.5) 40 (31.5) 36 (25.4) 46 (40.7)*** 26 (21.1)
Proteinuria
number (%)
71 (50.7)* 53 (36.3) 50 (38.8)** 31 (22.1) 53 (46.5)** 36 (29.8)
Significance of comparisons between the AKI group and non-exposed group: *p<0.05, **p≤0.01, ***p≤0.001.
Table 3 Number (%) of participants with albuminuria at 3 years, stratified by acute kidney injury severity, in the whole cohort
and in non-diabetics
Non-exposed AKI 1 AKI 2 AKI 3
Whole cohort 26 (21.1%) 31 (38.3%) 5 (29.4%) 10 (66.7%)
Non-diabetics 19 (18.1%) 20 (32.8%) 5 (33.3%) 5 (55.6%)
Figure 3 Mean estimated glomerular filtration rate (eGFR)
over time in individuals after acute kidney injury (AKI) with and
without chronic kidney disease progression. Estimated GFR
measurements are included for inhospital time points to
illustrate the effect of AKI; however, the absolute eGFR values
at these time points should be interpreted with caution as
patients are not in steady state. Error bars: 95% CI. *p<0.001,
**p=0.002.
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Nevertheless, the high incidence of CKD following AKI
may have other consequences; higher cardiovascular risk
as previously reported11 and in our cohort, a higher risk
of recurrent AKI. This is coherent with other descrip-
tions of AKI and CKD forming a bidirectional relation-
ship12 but also opens up the possibility of recurrent AKI
as a potentially modiﬁable risk factor in some patients.
Although the risk of CKD progression is increased
after AKI, not all individuals are affected. Identifying
those at greatest risk is important to target resources
appropriately and to reassure individuals at low risk of
adverse outcome. Factors identiﬁed previously to
increase the risk of CKD progression after AKI include
AKI severity,13 recurrent AKI,14 increased age15 and dia-
betes.13 The factors associated with CKD progression
that we identiﬁed are generally consistent with this,
though one of the strongest associations identiﬁed was
in those individuals with the greatest eGFR decline at
3 months compared with pre-AKI measurements. This
suggests that non-recovery of AKI is an important pre-
dictor of long-term outcome. This is consistent with a
study by D’Hoore et al,16 who demonstrated through
analysis of eGFR trajectories that CKD progression was
largely determined by non-recovery of AKI. However,
others have described an ongoing risk of CKD and mor-
tality, even in individuals with recovery of renal function
to <1.10%×baseline at hospital discharge.17 This discrep-
ancy could partly reﬂect limitations of creatinine-based
measures of renal function which can be affected by
changes in body mass during acute illness and may not
accurately reﬂect residual renal function at discharge, as
well as differences in timing of assessment. However, it is
also clear that risk prediction on an individual basis is
complex. Novel biomarkers and risk stratiﬁcation scores
validated using representative general hospital popula-
tions are needed to improve this. Identiﬁcation of high-
risk patients is important as this cohort may beneﬁt
from additional interventions. Potential approaches for
future intervention may be based on optimisation of
CKD management, in particular pharmacotherapy for
control of albuminuria and blood pressure. Indeed, ele-
vation in blood pressure has been demonstrated for
2 years after AKI in previously normotensive adults.18
This may reﬂect changes in renal salt handling following
injury, though prescribing changes after AKI may also be
clinically important.
Proteinuria and albuminuria following AKI are less
commonly reported, but our results suggested that both
are common and persistent. Similar observations were
seen in the Randomised Evaluation of Normal versus
Augmented Levels of RRT (RENAL) trial which showed
a prevalence of microalbuminuria or macroalbuminuria
of 42.1% at 90 days after episodes of severe AKI in a crit-
ical care setting.19 Similarly, in paediatric populations,
post-AKI proteinuria has been demonstrated.20
Albuminuria is a risk factor for AKI, and could predate
the development of AKI. This makes interpretation of
proteinuria challenging, as studies which recruit at the
time of AKI lack baseline measurement. Proteinuria
assessment is not commonly undertaken as screening in
the general population, meaning incidental baseline
measurements are likely to have been undertaken on
the basis of clinical need and be subject to indication
bias. Alternatively, albuminuria could also result from
renal damage sustained at the time of AKI. Animal work
demonstrates that the tubules have a role in albumin
reabsorption,21 so it is biologically plausible that tubular
injury could lead to albuminuria. We have shown previ-
ously how AKI in a well-characterised CKD population
does lead to increased albuminuria.22 Our current work
shows that high prevalence of proteinuria is sustained to
3 years after AKI, and there is a graded relationship of
AKI severity with prevalence of albuminuria. In addition,
the high incidence of albuminuria in those subgroups
less likely to have baseline albuminuria (such as non-
diabetics) would be consistent with proteinuria resulting
Table 4 Univariate and multivariate associations with chronic kidney disease progression at 3 years
Clinical variable
Univariate association
OR (95% CI)
Multivariate association
OR (95% CI)
Age 1.04 (1.00 to 1.08)* 1.03 (0.98 to 1.08)
Male gender 2.57 (1.15 to 5.76)* 2.88 (1.06 to 7.79)*
Diabetes 3.65 (1.61 to 8.26)* 5.23 (1.84 to 14.90)*
Baseline eGFR (mL/min) 1.00 (0.98 to 1.02) 1.01 (0.98 to 1.04)
Delta eGFR at 3 months (quartiles) mL/min
≤−8.20 14.13 (3.01 to 66.29)* 28.03 (5.37 to 146.31)*
−8.19 to −2.17 1.60 (0.29 to 8.91) 3.73 (0.65 to 21.48)
−2.16 to 5.21 2.68 (0.50 to 14.50) 4.48 (0.8 to 25.13)
≥5.22 1 (ref) 1 (ref)
Severe AKI (AKI stage 2 or 3) 1.26 (0.57 to 2.80)
Recurrent AKI 1.59 (0.73 to 3.45)
Hospital-acquired AKI 1.7 (0.75 to 3.88)
Albuminuria at 3 months 2.09 (0.93 to 4.71)
Proteinuria at 3 months 1.39 (0.66 to 2.92)
*p<0.005.
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from parenchymal damage sustained at the time of AKI.
Finally, the low ACR/PCR ratio of <0.4 seen in most par-
ticipants would be consistent with tubulointerstitial
injury.23
Our study does have some limitations. This was a pilot
study, powered to test feasibility of the methodology and
examine for a signal in our proposed study population.
This prevented certain analyses, such as the effect of
AKI aetiology, which need a larger sample size and this
will be investigated during the main study. A further
limitation is that this is a single-centre study and we lack
baseline proteinuria measurement. Key strengths are
that this is a prospective study with good matching
between exposed and non-exposed, and a high degree
of individual patient and AKI episode characterisation.
CONCLUSION
Our results demonstrate that even less severe AKI can
have signiﬁcant long-term effects on renal function and
proteinuria in a general hospital population. Although
few progress to end-stage renal disease within 3 years,
individuals are at increased risk of subsequent AKI, and
in the longer term, CKD progression and its attendant
cardiovascular risk. Ongoing large-scale studies will
better describe the natural history of AKI and hopefully
lead to validated risk predication models to identify indi-
viduals at greatest risk.
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